Department of Gastroenterology Surgery, Affiliated Hospital of Shaoxing University, Shaoxing 312000, Zhejiang Province, China.
Department of Nuclear Medicine, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China.
Pathol Res Pract. 2021 Feb;218:153322. doi: 10.1016/j.prp.2020.153322. Epub 2020 Dec 24.
Gastric cancer is considered as the third leading cause of deaths and the fifth most common cancers worldwide. Common treatment approaches include chemotherapy, radiation, gastric resection and targeted therapies. The emergence of gastric cancer immunotherapy has already shown some promising results and have altered the therapeutic procedures. Now, different combination therapies as well as novel immunotherapies targeting new molecules have been proposed. Despite ongoing investigations on the therapeutic options and significant advancements in this regard, the disease is poorly prognosed. In fact, limited therapeutic options and delayed diagnosis lead to the progression, dissemination and metastasis of the disease. Current immunotherapies are mostly based on cytotoxic immunocytes, monoclonal antibodies and gene transferred vaccines. The use of Immune checkpoint inhibitors (ICIs) have grown rapidly. In this review, we aimed to explore perspective and progression of different approaches of immunotherapy in the treatment of GC and the clinical outcomes reported so far. We also summarized the tumor immunosurveillance and tumor immunoescape.
胃癌被认为是全球第三大死亡原因和第五大常见癌症。常见的治疗方法包括化疗、放疗、胃切除术和靶向治疗。胃癌免疫疗法的出现已经显示出一些有希望的结果，并改变了治疗程序。现在，已经提出了不同的联合治疗方法以及针对新分子的新型免疫疗法。尽管对治疗选择进行了持续的研究并在这方面取得了重大进展，但该疾病的预后仍然很差。事实上，有限的治疗选择和诊断延迟导致疾病的进展、扩散和转移。目前的免疫疗法主要基于细胞毒性免疫细胞、单克隆抗体和基因转移疫苗。免疫检查点抑制剂（ICIs）的使用迅速增加。在这篇综述中，我们旨在探讨免疫疗法在 GC 治疗中的不同方法的前景和进展，以及迄今为止报告的临床结果。我们还总结了肿瘤免疫监视和肿瘤免疫逃逸。
